Precision Medicine Market Research Report - Global Forecast till 2027

Precision Medicine Market Research Report: Information by Ecosystem Players (Pharmaceuticals and Biotechnology Companies, Diagnostic Companies, Healthcare IT Specialists/Big Data Companies and Clinical Laboratories), Sub-Markets (Companion Diagnostics, Biomarker-Based Test, Targeted Therapeutics, Pharmacogenomics (PGX), Molecular Diagnostics and others), Therapeutics (Cancer/Oncology, Cardiovascular Disease (CVD), Central Nervous System, Infectious Diseases and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2027

ID: MRFR/Pharma/0420-CR | August 2019 | Region: Global | 313 pages

Please note that the assessment period of report has been updated from 2017-2025 to 2020-2027. Cordially fill the sample form for updated data.

Market Overview


The precision medicine market is one of the fastest evolving markets of recent times. The estimated precision medicine market valuation by the year 2025 is supposed to reach around USD 126.14 billion. The CAGR or compound annual growth rate of the market is predicted to be 12.48 percent during the forecast period (2017-2025).


The precision medicine industry is the upcoming trend in the healthcare sector which is progressing rapidly over the years. The precision medicine market trends, also known as personalized medicines, came to existence in 2003, and since then, it has ruled the market of the healthcare industry. These individualized medicines are the primary focus of healthcare departments that works on human genome overall sequencing. The modern and advanced technological developments have produced a path of numerous opportunities to present new medical, scientific, and business models.


The precision medicine market enables the involvement of the patient in taking personal healthcare and provides more targeted therapies to the individuals, which will boost the precision medicine market growth in the upcoming years. Rapid development in technologies such as ultra-high-throughput technologies and next-generation sequencing technologies decides the future of precision medicine. The increasing prevalence of various genetic diseases is projecting the personalized medicine market potential to extreme limits. The introduction of biotech and pharma industries with big data healthcare companies will result in propelling the precision medicine market growth.


New and advanced treatment of cancer is closely associated with precision medicines. The genetic mutation of individuals is different, and understanding it will allow clinicians to prescribe correct and specific medicines to patients according to their tumor type. These medicines will help to combat the tumors based on genetic mutations, which is creating a heavy demand for the personalized medicine industry. In the treatment of breast cancer, doctors are now looking at genome analysis which will allow them to determine specific treatments for the patients. Physicians are watching out the DNA testing report of BRCA gene mutation in women along with the family history of ovarian or breast cancer.


The continuous developments in the precision medicine market will fuel the market growth to attain its momentum. The integration of biotech and pharma industries with bigdata health care companies is another factor that will project the market value of the precision medicine industry to higher levels in the near future.


The report describes the inside information of the precision medicine market along with its forecast market valuation and possible growth rate. It covers the analysis of COVID19 impact on the personalized medicine market and discusses the market dynamics, including opportunities and threats in market growth. The report includes the major prominent players of the precision medicine market and provides details about market segmentation. It also puts light on several regions that can influence the precision medicine market growth in forecast years.


COVID19 Analysis


The outbreak of the COVID19 pandemic created havoc worldwide and impacted adversely the financial as well as the health sector. The growth rate of the global economy started declining towards a lower extent and will require further many years for recovery. Various businesses and industries faced heavy financial losses and witnessed a lower phase in the market growth rate. The lockdown restrictions resulted in the closure of many industrial operations and manufacturing processes. However, according to the precision medicine informatics market analysis,themarket sustained its growth rate even in these difficult times.


The global health crisis resulted in immense demand for medicines in the healthcare sector. The rising rate of diseases required personalized medicines that will help individuals to cure better. The health crisis is increasing the demand for individualized medicines, which upsurges the potential of the precision medicine market. The escalating cases of genome mutation diseases need the help of the precision medicine industry, which will lead to the expansion of blockchain precision medicine market size during the forecast period.


Market Dynamics



  • Major drivers of the market


The precision medicine market is emerging quickly in the global economy and will attain maximum heights in the upcoming years. The recent development in technologies like ultra-high-throughput sequencing and next-generation sequencing provide a better understanding of patient’s health. The precision medicine market involves individuals in their personal healthcare, which provides accurate prescriptions on a patient and progresses the precision medicine market potential to a greater extent. In recent times, there is a significant increase in the number of cases of genetic diseases. The changes in genetic mutation are different in every individual, so it requires in-depth testing and personalized medicines.


Gnome medicine is immensely helpful for treating cancer; therefore, many cancer care clinics are utilizing it for curing the disease. The advanced technologies aid physicians to understand the patient’s genetic mutations regarding different tumor types and allow them to prescribe accurate and specific medicines to individuals according to their tumor type. Certain forms of breast cancer require analysis of genetic mutations to determine the specific treatment for the patient. Doctors look for the BRCA gene mutation in women through DNA testing along with the family history of ovarian or breast cancer and give personalized medicines for the same. All these treatments thrust the personalized medicine industry to greater heights. The integration of biotech and pharma industries with bigdata health care companies will provide extensive support for the precision medicine market growth.



  • Significant opportunities for the market


The global precision medicine market is exhilarating at a rapid pace over the years, and the size of precision medicine market opportunity will fuel the market growth in upcoming times. Modern and advanced technology development has resulted in increasing demand for the precision medicine industry. Technology development such as ultra-high-throughput sequencing and next-generation sequencing has enabled more specific and targeted therapies for patients. The increasing prevalence of genetic diseases also creates an extreme surge of demand for personalized medicines in the market. Through precision medicine diagnostic insights, doctors can understand the genetic mutations of the patients and help doctors to prescribe specific medicines to cure the patient’s disease. The introduction of pharma and biotech industries with bigdata health care industries will propel the precision medicine market growth in the forecast period.



  • Market Restraints


The precision medicine market is surely progressing to greater heights, but the increased costs of diagnosis can hinder the market potential. The diagnosis and treatment process includes a large amount of personal data, and there is a potential threat related to it that can constrain the growth of the precision medicine market. Strict regulations and standards hamper the expansion of personalized medicine market size. However, the increasing prevalence of genetic diseases and the demand for effective solutions will maintain the growth rate of the precision medicine market.



  • Market growth challenges


The lack of awareness about genetic diseases and applications of personalized medicines among people restrict the precision medicine market growth. The regulatory framework and reimbursement policies can hinder the potential of the precision medicine market. However, the rising demand for personalized medicines in the healthcare sector will expand the precision medicine market size during the forecast period.


Value Chain analysis


The precision medicine market report reflects that the revenue generation of the market by the end of 2025 will surpass its historical market value. The market valuation, according to the precision medicine report, will touch optimum limits in the upcoming years due to the increasing demand for individualized medicines. The revenue of the precision medicine market will continue to grow rapidly in the near future.


Segment Overview


The global precision medicine market is segregated into different parts on the basis of submarkets, therapeutics, and ecosystem players. The precision medicine market segmentation on the basis of sub-markets includes biomarker-based tests, companion diagnostics, pharmacogenomics or PGX, targeted therapeutics, molecular diagnostics, and many more.


On the basis of therapeutics, the global precision medicine market segment comprises cardiovascular disease or CVD, central nervous system, cancer or oncology, infectious disease, and others. Among all the diseases, the oncology precision medicine market is going to progress a lot during the forecast period. The ecosystem players segment involves diagnostics companies, pharmaceuticals and biotechnology companies, clinical laboratories, healthcare IT specialists or big data companies, and many more.


Regional Analysis


The precision medicine market analysis is studied in various geographical areas like the Americas, Asia Pacific, Europe, Middle East, and Africa. The Americas will hold the majority share in the global precision medicine market. The US personalized medicine market share will be the most progressing one in the global market growth, and the advanced gene mapping technologies will help to expand the US personalized medicine market size.


The European region has better diagnostics tools, drugs, and electronic health care records, which will make it the second-largest shareholder of the precision medicine market. In the Asia Pacific region, the Singapore precision medicine market will outgrow the other market share as increased disposable income and better healthcare infrastructure are available there, which will propel the market growth in the forecast years.


Competitive Landscape of the market


The precision medicine top companies and major market players are:



  • Almac Group, Ltd.

  • ABBOTT LABORATORIES

  • bioMérieux SA

  • ASURAGEN, Inc.

  • Cepheid Inc.

  • GE Healthcare

  • CETICS Healthcare Technologies GmbH

  • Intomics A/S

  • Glaxosmithkline Plc (GSK)

  • LABORATORY CORPORATION OF AMERICA HOLDINGS

  • Johnson & Johnson

  • BIOBASE GmbH (Subsidiary)

  • Pfizer Inc, Qiagen

  • Medtronic, Novartis

  • Randox Laboratories Ltd

  • Quest Diagnostics Inc.

  • Takeda Pharmaceutical Company Limited

  • Roche Holding AG-Br

  • Sanofi Pharma

  • Caris Life Sciences

  • Teva Pharmaceutical Industries Ltd.

  • HealthCore, Inc.

  • AB-Biotics SA

  • Molecular Health GmbH, and Precision for Medicine

  • Intel Corporation

  • IBM

  • InnVentis



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 126.14 Billion
  • 2027: Significant Value
  •   CAGR   12.48 % (2017-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Ecosystem Players, Sub-Markets and Therapeutics
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abbott Laboratories (USA), Ab-Biotics Sa (USA), Almac Group Ltd. (UK), Asuragen Inc (USA), Biobase Gmbh (Germany), Biomérieux Sa (France), Caris Life Sciences (USA), Cepheid Inc. (USA), Cetics Healthcare Technologies Gmbh (Germany), Ge Healthcare (USA), Glaxosmithkline PLC (UK), Healthcore Inc. (USA), IBM (USA), Innventis (Israel), Intel Corporation (USA), Johnson & Johnson (USA), Laboratory Corporation Of America Holdings (USA), Medtronic (USA), Molecular Health Gmbh (Germany), Novartis (Switzerland), Pfizer Inc. (USA), Qiagen (Germany), Quest Diagnostics Inc (USA), Randox Laboratories Ltd. (UK), Sanofi Pharma (France), Takeda Pharmaceutical Company Limited (Japan), and Teva Pharmaceutical Industries Ltd. (Israel)
      Key Market Opportunities   global health crisis resulted in immense demand for medicines in the healthcare sector
      Key Market Drivers

  • rising rate of diseases required personalized medicines
  • health crisis is increasing the demand for individualized medicines


  • Frequently Asked Questions (FAQ) :


    Precision Medicine Market is projected to grow at an 12.48% CAGR between 2020-2027.

    Precision Medicine Market is predicted to touch USD 126.14 billion by 2022.

    Americas are predicted to have the highest share in the Precision Medicine Market.

    Increasing prevalence of genetic diseases and integration of big data with biotech and pharma companies are driving market growth.

    Strict regulations and standards, threat to personal data, and high diagnostic cost may limit market growth.

    1 Report Scope

    1.1 Scope of the Study 26

    1.2 Precision Medicine: Report Coverage 27

    1.3 Research Methodology 29

    1.3.1 Research Methodology for the Global Market Study 30

    1.3.1.1 Geographical Analysis 30

    1.3.1.2 Demand Side & Supply Side Analysis 31

    1.3.1.3 Data Synthesis and Bridging 31

    1.3.2 Global Precision Medicine: Research Methodology 32

    1.3.3 Key Data Point Sources 33

    1.3.3.1 Data Points Taken from Secondary Sources 33

    1.3.3.2 Data Points Taken from Primary Sources 33

    1.4 Report Description 34

    2 Executive Summary

    3 Market Overview

    3.1 Introduction 42

    3.2 Market Timeline 42

    3.3 Key Participants, Strategies & Developments 50

    3.3.1 Government Agencies 50

    3.3.2 Academic Institutions 50

    3.3.3 Device & Service Providers 51

    3.4 Key Market Strategies and Developments 51

    3.4.1 Introduction 51

    3.4.2 Partnerships, Agreements, and collaborations 52

    3.4.3 Mergers & Acquisitions 54

    3.4.4 Product Development and Launch 56

    3.4.5 Business Expansion/Contracts 57

    3.4.6 Patents, Approvals, and Certifications 59

    3.4.7 Others (Events & Recognitions) 60

    4 Market Dynamics

    4.1 Introduction 61

    4.2 Market Drivers 62

    4.2.1 Patients Involvement in Personal Healthcare 62

    4.2.2 Technologies Driving the Market (Next-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)..64

    4.2.3 Increase in Genetic Diseases 64

    4.2.4 potential for More Targeted Therapies 65

    4.2.5 Integration of Big Data Healthcare Companies with Pharma & Biotech Companies 65

    4.3 Market Challenges 66

    4.3.1 Potential Threat to Personal Data 66

    4.3.2 High Diagnostic Cost as a Barrier 67

    4.3.3 Potential Risk of Hardware or Software Failure 68

    4.3.4 Stringent Regulations and Standards 68

    4.3.5 Lack of Awareness about the Possible Applications of Precision Medicine 70

    4.3.6 Reimbursement Policies and Regulatory Framework 71

    4.3.7 Limited Knowledge About the Application of Test and Techniques 71

    4.3.8 Lack of Research and Evidences Creating Hindrances in its Application 72

    4.4 Market Opportunities 73

    4.4.1 Introduction of Precision Medicine Solutions in Developing Economies 73

    4.4.2 Downsizing the Cost of Genome Sequencing to Three Digits 74

    5 Industry Dynamics

    5.1 Value Chain Analysis 76

    5.1.1 Device Manufacturer & Drug Producers 77

    5.1.2 Healthcare Providers 77

    5.1.3 Healthcare ITs or Big Data Companies 77

    5.1.4 Regulators 77

    5.1.5 Third Party Payers 78

    5.1.6 Patients 78

    5.2 Porter Five Force Analysis 78

    5.2.1 Bargaining Power of Buyer (Patient) 79

    5.2.2 Bargaining Power of Supplier 80

    5.2.3 Threat from Substitute 82

    5.2.4 Threat from a New Entrant 83

    5.2.5 Intensity of Competitive Rivalry 84

    6 Consortiums, Certification, Regulations, and Standards

    6.1 Introduction 85

    6.1.1 Regulatory Bodies 86

    6.1.1.1 Food and Drug Administration (FDA) 89

    6.1.1.2 Medicines and Healthcare products Regulatory Agency (MHRA) 91

    6.1.1.3 Therapeutic Goods Administration (TGA)-Australia 91

    6.1.1.4 Conformité Européenne (CE) 92

    6.1.2 Consortiums 92

    6.1.3 Alliances/Associations 94

    7 Global Precision Medicine Market by Ecosystem Players

    7.1 Introduction 96

    7.1.1 Market Statistics 97

    7.2 Pharmaceuticals and Biotechnology Companies 99

    7.2.1 Key Market Trends, Developments, and Participants 105

    7.2.1.1 Market Trends 105

    7.2.1.2 Market Developments 105

    7.2.1.3 Key Participants 106

    7.3 Diagnostic Companies 107

    7.3.1 Key Market Trends, Developments, and Participants 111

    7.3.1.1 Market Trends 111

    7.3.1.2 Market Developments 112

    7.3.1.3 Key Participants 112

    7.4 Healthcare it Specialists/Big Data Companies 113

    7.4.1 Key Market Trends, Developments, and Participants 119

    7.4.1.1 Market Trends 119

    7.4.1.2 Market Developments 120

    7.4.1.3 Key Participants 121

    7.5 Clinical Laboratories 121

    7.5.1 Key Market Trends, Developments, and Participants 125

    7.5.1.1 Regulatory Bodies and Compliances 125

    7.5.1.2 Market Trends 126

    7.5.1.3 Key Participants 127

    8 Global Precision Medicine Market by Sub-Markets

    8.1 Introduction 128

    8.1.1 Market Statistics 129

    8.2 Companion Diagnostics 131

    8.3 Biomarker-Based Test 135

    8.3.1 Role of Biobanking into Biomarker 137

    8.3.2 Key Participants 141

    8.4 Targeted Therapeutics 142

    8.4.1 Key Participants 144

    8.5 Pharmacogenomics (PGX) 144

    8.5.1 Key Market Trends, Developments, and Participants 149

    8.5.1.1 Market Trends 149

    8.5.1.2 Market Developments 150

    8.5.1.3 Key Participants 151

    8.6 Molecular Diagnostics 151

    8.7 Others 157

    8.7.1 Next-Generation Sequencing 159

    8.7.2 Consumer Genomics 159

    8.7.2.1 Key Participants 159

    8.7.3 3D Printing 160

    8.7.4 Prosthetics Market 160

    8.7.5 Human Tissues Market 160

    9 Global Precision Medicine Market by Therapeutics

    9.1 Introduction 162

    9.1.1 Market Statistics 163

    9.2 Cancer/Oncology 164

    9.2.1 Market Statistics 165

    9.2.2 Types of Cancer 167

    9.2.3 Drugs & Tests 170

    9.2.4 Key Market Trends, Developments, and Participants 172

    9.2.4.1 Market Trends 172

    9.2.4.2 Market Developments 172

    9.2.4.3 Key Participants 174

    9.3 Cardiovascular Disease (CVD) 175

    9.3.1 Market Statistics 176

    9.3.2 Drugs & Tests 179

    9.3.3 Market Trends and Market Developments 180

    9.3.3.1 Market Trend 180

    9.3.3.2 Market Developments 181

    9.3.3.3 Key Participants 181

    9.4 Central Nervous System 182

    9.4.1 Market Statistics 182

    9.4.2 Neurological 184

    9.4.2.1 Neurological Drugs & Tests 185

    9.4.3 Psychiatric Disorders 186

    9.4.3.1 Psychiatric Disorder Drugs & Tests 186

    9.4.4 Market Tends & Market Developments 188

    9.4.4.1 Market Trends 188

    9.4.4.2 Key Developments 188

    9.4.4.3 Key Participants 188

    9.5 Infectious Diseases 189

    9.5.1 Market Statistics 189

    9.5.2 Infectious Diseases Drugs & Tests 192

    9.5.3 Market Developments & Participants 193

    9.5.3.1 Key Developments 193

    9.5.3.2 Key Participants 194

    9.6 Others 194

    9.6.1 Market Statistics 195

    9.6.2 Market trends, Developments & Participants 200

    9.6.2.1 Market Trends 200

    9.6.2.2 Key Developments 200

    9.6.2.3 Key Participants 201

    10 Global Precision Medicine Market, by Geography

    10.1 Introduction 202

    10.1.1 Market Statistics 203

    10.2 The Americas 204

    10.2.1 North America 207

    10.2.1.1 US. 208

    10.2.1.2 Canada 209

    10.2.1.3 Others 210

    10.2.1.4 Key Market Trends, Developments, and Participants 210

    10.2.1.5 Regulations and Compliances 210

    10.2.1.6 Market Trends 210

    10.2.1.7 Market Developments 211

    10.2.1.8 Key Participants 211

    10.2.2 South America 212

    10.2.2.1 Key Market Trends, Developments, and Participants 212

    10.2.2.2 Regulations and Compliances 212

    10.2.2.3 Market Trends 212

    10.2.2.4 Key Participants 212

    10.3 Europe 213

    10.3.1 Key Market Trends, Developments and Participants 216

    10.3.1.1 Regulations and Compliances 216

    10.3.1.2 Market Developments 216

    10.3.1.3 Key Participants 218

    10.4 Asia-Pacific (APAC) 218

    10.4.1 Key Market Trends, Developments, and Participants 222

    10.4.1.1 Market Developments 222

    10.4.1.2 Key Participants 223

    10.5 Rest of the World/Midde East & Africa (MEA) 223

    10.5.1 Africa 225

    10.5.1.1 Middle East 226

    10.5.2 Key Market Developments and Participants 226

    10.5.2.1 Market Developments 226

    10.5.2.2 Key Participants 226

    11 Company Profiles

    11.1 Abbott Laboratories 227

    11.1.1 Overview 227

    11.1.2 Financials 228

    11.1.2.1 Overall Financials 228

    11.1.2.2 Financials by Segment 228

    11.1.2.3 Financials by Region 229

    11.1.2.4 Key Developments 229

    11.1.3 SWOT Analysis 231

    11.2 Almac Group, Ltd. 232

    11.2.1 Overview 232

    11.2.2 Financials 232

    11.2.3 Key Developments 233

    11.2.4 SWOT Analysis 234

    11.3 Asuragen, Inc. 235

    11.3.1 Overview 235

    11.3.2 Financials 235

    11.3.3 Key Developments 236

    11.3.4 SWOT Analysis 237

    11.4 BioMérieux SA 238

    11.4.1 Overview 238

    11.4.2 Financials 239

    11.4.2.1 Overall Financials 239

    11.4.2.2 Financials by Region 239

    11.4.2.3 Financials by Segment 240

    11.4.3 Key Developments 240

    11.4.4 Swot Analysis 242

    11.5 Cepheid Inc. 243

    11.5.1 Overview 243

    11.5.2 Financials 244

    11.5.2.1 Overall Financials 244

    11.5.2.2 Net Revenue by Segment 245

    11.5.2.3 Net Revenue by Region 245

    11.5.3 Key Developments 246

    11.5.4 SWOT Analysis 247

    11.6 CETICS Healthcare Technologies GmbH 248

    11.6.1 Overview 248

    11.6.2 Financials 248

    11.6.3 Key Developments 249

    11.6.4 SWOT Analysis 250

    11.7 GE Healthcare 251

    11.7.1 Overview 251

    11.7.2 Financials 252

    11.7.2.1 Overall Financials 252

    11.7.2.2 Net Revenue by Segment 253

    11.7.2.3 Financial Summary 254

    11.7.3 Key Developments 254

    11.8 Glaxosmithkline Plc (GSK) 256

    11.8.1 Overview 256

    11.8.2 Financials 257

    11.8.2.1 Overall Financials 257

    11.8.2.2 Financials by Segment 257

    11.8.2.3 Financials by Region 258

    11.8.2.4 Financials by Therapeutics 258

    11.9 Intomics A/S 259

    11.9.1 Overview 259

    11.9.2 Financials 259

    11.9.3 Key Developments 259

    11.9.4 SWOT Analysis 260

    11.10 Johnson & Johnson 261

    11.10.1 Overview 261

    11.10.2 Financials 262

    11.10.2.1 Overall Financials 262

    11.10.2.2 Net Revenue by Segment 262

    11.10.2.3 Net revenue by Region 263

    11.10.3 Key Developments 263

    11.11 Laboratory Corporation of America Holdings 264

    11.11.1 Overview 264

    11.11.2 Financials 265

    11.11.2.1 Overall Financials 265

    11.11.2.2 Financials by Segment 266

    11.11.3 Key Developments 266

    11.11.4 SWOT Analysis 268

    11.12 Medtronic 269

    11.12.1 Overview 269

    11.12.2 Financials 270

    11.12.2.1 Overall Financials 270

    11.12.3 Key Developments 270

    11.13 Novartis 272

    11.13.1 Overview 272

    11.13.2 Financials 273

    11.13.2.1 Overall Financials 273

    11.13.2.2 Financials by Region 274

    11.13.2.3 Financials by Segment 274

    11.14 Pfizer Inc. 275

    11.14.1 Overview 275

    11.14.2 Financials 276

    11.14.2.1 Overall Financials 276

    11.14.2.2 Net Revenue by Segment 276

    11.14.2.3 Net Revenue by Region 277

    11.14.3 Key Developments 277

    11.14.4 Swot Analysis 279

    11.15 Qiagen 280

    11.15.1 Overview 280

    11.16 Biobase GmbH (Subsidiary) 281

    11.16.1 Overview 281

    11.16.2 Financials 282

    11.16.2.1 Overall Financials 282

    11.16.3 Key Developments (Biobase) 283

    11.17 Quest Diagnostics Inc 284

    11.17.1 Overview 284

    11.17.2 Financials 285

    11.17.2.1 Overall Financials 285

    11.17.2.2 Net Revenue by Segment 286

    11.17.3 Key Developments 286

    11.17.4 SWOT Analysis 288

    11.18 Randox Laboratories Ltd. 289

    11.18.1 Overview 289

    11.18.2 Financials 289

    11.18.3 Key Developments 290

    11.18.4 SWOT Analysis 291

    11.19 Roche Holding AG-BR 292

    11.19.1 Overview 292

    11.19.2 Financials 293

    11.19.2.1 Overall Financials 293

    11.19.2.2 Net Revenue by Segment 293

    11.19.3 Key Developments 294

    11.19.4 SWOT Analysis 295

    11.20 Sanofi Pharma 296

    11.20.1 Overview 296

    11.20.2 Financials 297

    11.20.2.1 Overall Financials 297

    11.20.2.2 Net Revenue by Segment 297

    11.21 Takeda Pharmaceutical Company Limited 298

    11.21.1 Overview 298

    11.21.2 Financials 299

    11.21.2.1 Overall Financials 299

    11.21.3 Key Developments 299

    11.21.4 SWOT Analysis 301

    11.22 Teva Pharmaceutical Industries Ltd. 302

    11.22.1 Overview 302

    11.22.2 Financials 303

    11.22.2.1 Overall Financials 303

    11.22.2.2 Net Revenue by Segment 303

    11.22.2.3 Net Revenue by Segment 304

    11.22.3 Key Developments 304

    11.22.4 SWOT Analysis 307

    11.23 AB-Biotics SA 308

    11.23.1 Overview 308

    11.24 Caris Life Sciences 309

    11.24.1 Overview 309

    11.25 HealthCore, Inc. 310

    11.25.1 Overview 310

    11.26 IBM 311

    11.26.1 Overview 311

    11.27 InnVentis 312

    11.27.1 Overview 312

    11.28 Intel Corporation 313

    11.28.1 Overview 313

    11.29 Molecular Health GmbH 314

    11.29.1 Overview 314

    11.30 Precision for Medicine 315

    11.30.1 Overview 315

    12 List of Tables

    TABLE 1 LEADING COMPANIES IN THE PRECISION MEDICINE MARKET 37

    TABLE 2 DOWNSIZING COST OF GENOME SEQUENCING 74

    TABLE 3 FACTORS IMPACTING THE BUYERS BARGAINING POWER 80

    TABLE 4 FACTORS IMPACTING THE SUPPLIERS BARGAINING POWER 81

    TABLE 5 FACTORS IMPACTING THE THREAT FROM SUBSTITUTE 82

    TABLE 6 FACTORS IMPACTING THE THREAT FROM NEW ENTRANT 83

    TABLE 7 FACTORS IMPACTING THE DEGREE OF COMPETITION 84

    TABLE 8 REGULATORY BODIES IN PRECISION MEDICINE MARKET 87

    TABLE 9 CONSORTIUMS IN PRECISION MEDICINE MARKET 93

    TABLE 10 ALLIANCES/ASSOCIATIONSIN PRECISION MEDICINE MARKET 94

    TABLE 11 GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2020–2027 (USD BILLION) 97

    TABLE 12 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,

    2020–2027 (USD BILLION) 100

    TABLE 13 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION) 101

    TABLE 14 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY,

    2020–2027 (USD BILLION) 102

    TABLE 15 KEY DEVELOPMENTS IN PHARMA & BIOTECH COMPANIES (2020) 105

    TABLE 16 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,

    2020–2027 (USD BILLION) 107

    TABLE 17 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION) 108

    TABLE 18 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY GEOGRAPHY, 2020–2027 (USD BILLION) 109

    TABLE 19 KEY DEVELOPMENTS IN DIAGNOSTIC COMPANIES(2020) 112

    TABLE 20 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY SUB-MARKET TYPES, 2020–2027 (USD BILLION) 113

    TABLE 21 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION) 114

    TABLE 22 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY GEOGRAPHY, 2020–2027 (USD BILLION) 115

    TABLE 23 KEY DEVELOPMENTS IN HEALTHCARE IT/BIG DATA COMPANIES(2020) 120

    TABLE 24 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY SUB-MARKET TYPES, 2020–2027 (USD BILLION) 122

    TABLE 25 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION) 123

    TABLE 26 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY GEOGRAPHY, 2020–2027 (USD BILLION) 124

    TABLE 27 GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2020–2027 (USD BILLION) 129

    TABLE 28 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 131

    TABLE 29 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 132

    TABLE 30 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES 133

    TABLE 31 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 135

    TABLE 32 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 136

    TABLE 33 LIST OF BIOBANKS 138

    TABLE 34 EXAMPLES OF BIOBANKING INITIATIVES ACROSS SELECTED OECD COUNTRIES 139

    TABLE 35 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 142

    TABLE 36 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 143

    TABLE 37 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 145

    TABLE 38 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 146

    TABLE 39 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 152

    TABLE 40 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 153

    TABLE 41 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 157

    TABLE 42 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE,

    BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 158

    TABLE 43 GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2020–2027 (USD BILLION) 163

    TABLE 44 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

    2020–2027 (USD BILLION) 165

    TABLE 45 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2020–2027 (USD BILLION) 166

    TABLE 46 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2020–2027 (USD BILLION) 167

    TABLE 47 PRECISION MEDICINE DRUGS AND RELEVANT GENES: ONCOLOGY 170

    TABLE 48 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO ONCOLOGY 171

    TABLE 49 PRECISION MEDICINE MARKET KEY DEVELOPMENTS (2020–2020) 172

    TABLE 50 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2020–2027 (USD BILLION) 176

    TABLE 51 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2020–2027 (USD BILLION) 177

    TABLE 52 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2020–2027 (USD MILLION) 178

    TABLE 53 PRECISION MEDICINE DRUGS AND RELEVANT GENES: CARDIOVASCULAR 179

    TABLE 54 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO CARDIOVASCULAR 180

    TABLE 55 KEY DEVELOPMENTS (2020–2020) 181

    TABLE 56 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 182

    TABLE 57 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2020–2027 (USD MILLION) 183

    TABLE 58 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2020–2027 (USD MILLION) 184

    TABLE 59 PRECISION MEDICINE DRUGS AND RELEVANT GENES: NEUROLOGY 185

    TABLE 60 PRECISION MEDICINE DRUGS AND RELEVANTGENES: PSYCHIATRIC DISORDERS 186

    TABLE 61 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO PSYCHIATRIC DISORDERS 187

    TABLE 62 PSYCHIATRIC DISORDERS: PRECISION MEDICINE MARKET KEY DEVELOPMENTS (2020–2020) 188

    TABLE 63 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

    2020–2027 (USD MILLION) 189

    TABLE 64 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,

    2020–2027 (USD MILLION) 190

    TABLE 65 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY,

    2020–2027 (USD MILLION) 191

    TABLE 66 PRECISION MEDICINE DRUGS AND RELEVANT GENES: INFECTIOUS DISEASES 192

    TABLE 67 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

    2020–2027 (USD MILLION) 195

    TABLE 68 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,

    2020–2027 (USD MILLION) 196

    TABLE 69 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY,

    2020–2027 (USD MILLION) 197

    TABLE 70 PRECISION MEDICINE DRUGS AND RELEVANT GENES: OTHER DISEASES 198

    TABLE 71 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO OTHER DISEASES 199

    TABLE 72 GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2020–2027 (USD BILLION) 203

    TABLE 73 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

    2020–2027 (USD BILLION) 204

    TABLE 74 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

    2020–2027 (USD BILLION) 205

    TABLE 75 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,

    2020–2027 (USD BILLION) 206

    TABLE 76 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,

    2020–2027 (USD BILLION) 213

    TABLE 77 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,

    2020–2027 (USD BILLION) 214

    TABLE 78 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2020–2027 (USD BILLION) 219

    TABLE 79 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,

    2020–2027 (USD MILLION) 220

    TABLE 80 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2020–2027 (USD MILLION) 224

    TABLE 81 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,

    2020–2027 (USD MILLION) 225

    13 List of Figures

    FIGURE 1 PRECISION MEDICINE MARKET STUDY 27

    FIGURE 2 PRECISION MEDICINE MARKET RESEARCH METHODOLOGY 29

    FIGURE 3 DIFFERENT PHASES OF RESEARCH METHODOLOGY FOR THE GLOBAL PRECISION MEDICINE MARKET 30

    FIGURE 4 PRECISION MEDICINE MARKET: RESEARCH METHODOLOGY 32

    FIGURE 5 GLOBAL PRECISION MEDICINE MARKET SHARE, BY ECOSYSTEM, 2020–2027 (USD BILLION) 38

    FIGURE 6 GLOBAL PRECISION MEDICINE MARKET SIZE, BY SUB-MARKET TYPE, 2020–2027 (BILLION) 39

    FIGURE 7 GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERPEUTIC APPLICATION, 2020–2027 (BILLION) 40

    FIGURE 8 GLOBAL PRECISION MEDICINE MARKET SIZE, BY GEOGRAPHY, 2020 – 2027 (USD BILLION) 41

    FIGURE 9 TIMELINE OF PRECISION MEDICINE 43

    FIGURE 10 PRECISION MEDICINE MARKET: BENEFITS 45

    FIGURE 11 EXAMPLES: APPLIED AREAS OF PRECISION MEDICINE 46

    FIGURE 12 ELEMENTS OF PRECISION MEDICINE MARKET TECHNOLOGY 47

    FIGURE 13 PRECISION MEDICINE MARKET : DIFFERENT TYPE OF DATA USED BY BIG DATA COMPANIES 48

    FIGURE 14 PRECISION MEDICINE MARKET : AREAS OF INTEREST 49

    FIGURE 15 PRECISION MEDICINE MARKET : PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2020) 53

    FIGURE 16 PRECISION MEDICINE MARKET : MERGERS & ACQUISITIONS (2020) 55

    FIGURE 17 PRECISION MEDICINE MARKET : KEY PRODUCT LAUNCH & DEVELOPMENTS (2020) 57

    FIGURE 18 PRECISION MEDICINE MARKET : KEY BUSINESS EXPANSIONS & CONTRACTS (2020) 58

    FIGURE 19 PRECISION MEDICINE MARKET : KEY PATENTS/ APPROVALS (2020) 59

    FIGURE 20 PRECISION MEDICINE MARKET: EVENTS & RECOGNITION (2020) 60

    FIGURE 21 PRECISION MEDICINE MARKET DRIVERS AND CHALLENGES 61

    FIGURE 22 BENEFITS OF PRECISION MEDICINE TO PATIENTS 63

    FIGURE 23 MAJOR BARRIERS CAUSED BY REGULATION AND STANDARDS 69

    FIGURE 24 FLOW CHART OF PRECISION MEDICINE MARKET 76

    FIGURE 25 PRECISION MEDICINE MARKET : PORTER FIVE FORCE ANALYSIS 79

    FIGURE 26 ROLES AND RESPONSIBILITIES OF HEALTHCARE POLICY MAKERS 86

    FIGURE 27 ROLE OF FDA IN PRECISION MEDICINE 90

    FIGURE 28 CLASSIFICATION OF MEDICAL DEVICES 91

    FIGURE 29 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS 98

    FIGURE 30 ROLE OF PHARMACEUTICALS AND BIOTECH COMPANIES 103

    FIGURE 31 PRECISION MEDICINE MARKET CHALLENGES FACED BY PHARMA & BIOTECH COMPANIES 104

    FIGURE 32 DIAGNOSTIC TESTS BENEFITS FOR STAKEHOLDERS 110

    FIGURE 33 CHALLENGES FACED BY DIAGNOSTIC COMPANIES 111

    FIGURE 34 BENEFITS OF BIG DATA 116

    FIGURE 35 TRANSFORMATION OF MEDICINE 117

    FIGURE 36 BASIC INGREDIENTS PROVIDED BY BIG DATA FOR PRECISION MEDICINE 118

    FIGURE 37 PRECISION MEDICINE MARKET CHALLENGES FACED BY BIG DATA COMPANIES 119